Capital Wealth Planning’s GSK GSK Stock Holding History

Capital Wealth Planning’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,771	Closed	-$241K	–	138
2023 Q1	$241K	Buy	+6,771	New	+$237K	﹤0.01%	129

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Wealth Planning's GSK Position: Q2 2023 in Review

Capital Wealth Planning sold out of GSK (GSK) in Q2 2023, closing a stake of 6,771 shares — an estimated $241K sold.

Capital Wealth Planning first reported a position in GSK in Q1 2023 and held it in 1 quarter. The position peaked at $241K in Q1 2023. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Capital Wealth Planning reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Capital Wealth Planning sold 6,771 GSK shares in Q2 2023, an estimated $241K.
Capital Wealth Planning first reported a position in GSK in Q1 2023 and held it in 1 quarter.
Capital Wealth Planning's GSK position peaked at $241K in Q1 2023.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Capital Wealth Planning's 13F filing for Q2 2023, filed 4 Aug 2023.